Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cidara plans IPO to fund antifungal pipeline

This article was originally published in Scrip

Executive Summary

Cidara Therapeutics, a San Diego firm focused on developing novel antifungals, both standard small molecules and bispecific molecules based on its immunotherapy technology platform, has filed a prospectus with the SEC for an initial public offering on Nasdaq of up to $69m, with net proceeds of up to $61.4m including full exercise of an over-allotment option. The firm, whose CEO Jeffrey Stein was formerly CEO of Cubist acquisition Trius Therapeutics, will invest the money into clinical development of the intravenous and topical forms of CD101 in candidemia/invasive candidiasis and acute and recurrent vulvovaginal candidiasis, respectively, through to the completion of Phase II trials, and the initiation of a pivotal Phase III trial of the topical product. It will also invest in the preclinical and early clinical studies of candidates from its Cloudbreak immunotherapy platform, and to expand that platform to other areas of infectious disease. Cidara recently closed a $42m series B fundraising.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028121

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel